GLP1R and diabetic kidney disease: With the assistance of RAS inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists, finerenone effectively reduces urinary protein and improves the inflammatory response, demonstrating relatively manageable safety in real-world DKD treatment.